• Ionis Pharmaceuticals dosed the first participant in the Phase 1-2 ASCEND trial of ION337 for Dravet syndrome.
• Open-label study tests safety in children ages 2-12; includes a 6-month single ascending dose phase.
• Program then moves to a 24-month multiple ascending dose phase with intrathecal dosing every 6 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713156157) on July 13, 2026, and is solely responsible for the information contained therein.